IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·IPUBLIC RECORDSEXCHANGERECEIPTSloadinglive·IMONEY TRAILEXCHANGESOURCESverifyinglive·IDATA SOURCESEXCHANGEFILINGSpublic recordslive·
← Leaderboard
CHRS
Ticker

CHRS

Congressional Trades
1
by 1 members
Ticker Intelligence Brief

Who in Congress traded CHRS, when, and what happened after?

A ticker-first view for retail/data users: latest disclosure, largest range, disclosure lag, party flow, contracts, lobbying, and source-linked receipts.

Latest receipt
Shri Thanedar
SELL · 2023-01-23
Largest range
$15K – $50K
Shri Thanedar
Slowest filing
7d
Shri Thanedar
Best vs SPY
—
No scored returns
Buys
0
0%
Sells
1
100%
Total Volume
$33K
midpoint
Unique Traders
1
members

Party Breakdown

Democrats1 · 100%
Republicans0 · 0%

💼 Lobbying Filings

all →
  • 2026-05-18$80K
    COHERUS BIOSCIENCES INC.
    Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
  • 2026-04-20$50K
    COHERUS BIOSCIENCES
    Issues related to federal drug reimbursement and domestic manufacturing policy.
  • 2026-04-19$60K
    COHERUS BIOSCIENCES INC
    Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry
  • 2026-03-09$80K
    COHERUS BIOSCIENCES INC.
    Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
  • 2026-01-19$50K
    COHERUS BIOSCIENCES
    Issues related to federal drug reimbursement and domestic manufacturing policy.
  • 2026-01-18$60K
    COHERUS BIOSCIENCES INC
    Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry
  • 2025-10-22$80K
    COHERUS BIOSCIENCES INC.
    Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.
  • 2025-10-18$50K
    COHERUS BIOSCIENCES
    Issues related to federal drug reimbursement and domestic manufacturing policy.
  • 2025-10-15$50K
    COHERUS BIOSCIENCES INC
    Issues related to domestic manufacturing of pharmaceuticals Federal financial support for the American Biotech Industry Federal Financial Support for the American Biotech Industry
  • 2025-08-18$125K
    COHERUS BIOSCIENCES INC.
    Issues related to oncology, Medicare coverage, domestic production of essential drugs, supply chain security, PILLS Act, Biosecure Act, Loans and grants for biologic production Issues related to drug development, oncology, IRA implementation, supply chain security, BIOSECURE as a policy matter, PILLS Act, and domestic production of essential drugs. Strategic National Stockpile of acute radiation syndrome medical counter measures. Administration for Strategic Preparedness & Response.

Congressional Momentum

buy vs. sell pressureDISTRIBUTING

Score 0–100: above 50 = net buying pressure, below 50 = net selling. Signal based on last 90 days.

Last 30 Days
No trades
Last 90 Days
No trades
All-Time
▼0
0 buys1 total1 sell
$0 buys · $33K sells

All Disclosed Trades

DateMemberActionAmountFiling DelayReceipt
2023-01-23DShri ThanedarSELL$15K – $50K7dreceipt →